Ritchie, M.D., staff dermatologist, chief of phototherapy and tele-dermatology at San Antonio Military Health System and principal investigator of the studies.
PHOTOEXPRESS SAN ANTONIO SKIN
"The early clinical results in two severe skin diseases and the lack of significant adverse events with GR-MD-02 is very encouraging, and we plan on presenting complete data at a scientific meeting in the future," said Simon A. The patient is continuing on therapy and approval has been submitted to identify and treat an additional two patients with severe atopic dermatitis. Following only four drug infusions, the patient has had a marked clinical effect with near resolution of pruritus, or itching, and regression of skin lesions.
GR-MD-02 was also used under an investigator-initiated study to treat a patient with severe atopic dermatitis who had been recalcitrant to multiple therapies over many years. The significant clinical improvement in the fifth patient is shown in the accompanying photographs the same degree of improvement was evident in all body regions.Ī photo accompanying this announcement is available at
PHOTOEXPRESS SAN ANTONIO FULL
The fifth patient, who also had the most severe baseline disease, had a 72% PASI improvement after the full thirteen infusions (24 weeks). All five patients had significant clinical improvement (mean of 52% improvement) as measured by an objective measurement, the PASI (Psoriasis Area and Severity Index). The Company now has complete data on the therapy of five patients with moderate-to severe plaque psoriasis for up to 24 weeks with 8 mg/kg doses of GR-MD-02 delivered every other week. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced its plans to identify a strategic partnership for its galectin-3 inhibitor GR-MD-02 for the treatment of serious skin diseases, including moderate-to-severe plaque psoriasis and severe atopic dermatitis. 10, 2016 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases 19.9 KB
0 kommentar(er)
